Source-grounded facts extracted from Tenaya Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tenaya Therapeutics, Inc. shareholders approved Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan at the 2026-05-27 meeting.
“The stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan.”
Tenaya Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-27 meeting.
“The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Tenaya Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-05-27 meeting.
“Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Tenaya Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026”
Tenaya Therapeutics, Inc. entered into Collaboration Agreement with Alnylam Pharmaceuticals, Inc. valued at up to $10.0 million (effective 2026-03-04).
“On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”)”
Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a”
Tomohiro Higa was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..
“Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.”
Chihiro Saito was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..
“Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company”
Faraz Ali was appointed as Interim Principal Financial Officer at Tenaya Therapeutics, Inc..
“Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.”
Leone Patterson departed as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..
“Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya”
Leone Patterson resigned as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..
“On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.”
Jin-Long Chen resigned as Director at Tenaya Therapeutics, Inc..
“On June 25, 2024, Jin-Long Chen submitted his resignation as a director of Tenaya Therapeutics, Inc.”
Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Tenaya Therapeutics, Inc. (“Tenaya”) issued a press release announcing Tenaya’s financial results for the quarter ended March 31, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”
Tenaya Therapeutics, Inc. announced a restructuring with charges of $1.3 million to $1.5 million (approximately 22% of the workforce).
“Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce. In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.